FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912154848> ?p ?o ?g. }

• W2912154848 endingPage "2135" @default.
• W2912154848 startingPage "2135" @default.
• W2912154848 abstract "Abstract The outcome of patients undergoing allogeneic hematopoietic stem cell transplantation (HCT) has improved over the past decades. However, the outcome of critically ill patients undergoing HCT admitted to intensive care units (ICU) is still considered dismal. Factors that predict outcome of this patient cohort and allow a proper triage assessment before and after ICU admission are still under discussion with no existing clinical standards. To identify accessible predictive factors, we retrospectively evaluated the outcomes of 127 HCT patients who required admission to the ICU between 2009 and 2016 out of 580 (21.9%) HCT patients during this period (Table 1) in our center. In general, 72 of 127 patients (56.7%) died on the ICU, which is in line with previous publications. Respiratory failure was the leading cause for ICU admission (70%). The median age was 50 y (+/-12.7) (range, 19-73y) and ICU admission mainly occurred after the engraftment period (≥30 days after HCT) in 107 patients. The median time from HCT to ICU transfer was 228 days (+/-419.8). To better understand factors that predict the survival of HCT patients upon ICU admission, we assessed 73 clinical factors and parameters. In the according multivariate analysis, three out of 73 factors negatively impacted ICU mortality as well as overall survival (OS). These were septic shock (HR:3.27, p=0.002), SOFA score >9 (HR:5.93, p<0.004) and C-reactive protein (CRP) levels >200 mg/l (HR:2.1, p=0.003). HLA-identical donors positively impacted only on ICU survival (HR:0.39, p=0.005), suggesting a benefit in this particular patient cohort. In contrast to previous publications, invasive mechanical ventilation and renal replacement therapy were no independent prognostic factors in any multivariate analysis in our cohort (p=0.63 and p=0.56, respectively). Twenty-eight (50.9%) out of 55 ICU-survivors died after transfer from the ICU to the general ward. Main causes of death were infections (53.6%) and respiratory failure (42.9%). Of note, 12 patients (42.9%) out of these 28 had to be readmitted to the ICU, suggesting the necessity of an ICU-to-Intermediate care step-down, allowing a close monitoring after ICU dismissal. Only 27 patients (21.3%) of the initial cohort were discharged from the hospital, resulting in a hospital mortality rate of 78.7% (100/127 patients) and translating into a 1-year overall survival (OS) rate of 7.8% for all patients in our cohort. Independent predictors for hospital mortality were multiorgan failure (HR:2.45, p=0.016), SOFA score >9 (HR:1.86, p=0.01) and C-reactive protein levels > 200 mg/l (HR:2.15, p=0.002). In summary we identified a high SOFA score and a high CRP value as predictors for a negative OS of HCT patients who required admission to the ICU. Although a prospective validation is beneficial, both factors can be assessed routinely and potentially allow the identification of high risk HCT patients that require a timely admission to ICU. In addition, close monitoring through a stepdown to intermediate care after ICU should be considered to improve mortality of this fragile patient cohort. Disclosures Döhner: Pfizer: Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Bristol Myers Squibb: Research Funding; Astex Pharmaceuticals: Consultancy, Honoraria; Agios: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Seattle Genetics: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Celator: Consultancy, Honoraria; Astellas: Consultancy, Honoraria; Bristol Myers Squibb: Research Funding; AROG Pharmaceuticals: Research Funding; Novartis: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Astellas: Consultancy, Honoraria; Sunesis: Consultancy, Honoraria, Research Funding; AROG Pharmaceuticals: Research Funding; Janssen: Consultancy, Honoraria; Astex Pharmaceuticals: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding; Seattle Genetics: Consultancy, Honoraria; Agios: Consultancy, Honoraria; Jazz: Consultancy, Honoraria; Pfizer: Research Funding; Jazz: Consultancy, Honoraria; Celgene: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria; Celator: Consultancy, Honoraria; Sunesis: Consultancy, Honoraria, Research Funding." @default.
• W2912154848 created "2019-02-21" @default.
• W2912154848 creator A5002578778 @default.
• W2912154848 creator A5005122036 @default.
• W2912154848 creator A5021660874 @default.
• W2912154848 creator A5028030321 @default.
• W2912154848 creator A5062140174 @default.
• W2912154848 creator A5068478538 @default.
• W2912154848 creator A5074684369 @default.
• W2912154848 creator A5075899439 @default.
• W2912154848 creator A5082158998 @default.
• W2912154848 creator A5089395073 @default.
• W2912154848 date "2018-11-29" @default.
• W2912154848 modified "2023-09-30" @default.
• W2912154848 title "Risk Factors Determining the Outcome of Critically Ill Allogeneic Hematopoietic Stem Cell Transplantation Patients: Time to Step Down?" @default.
• W2912154848 doi "https://doi.org/10.1182/blood-2018-99-115280" @default.
• W2912154848 hasPublicationYear "2018" @default.
• W2912154848 type Work @default.
• W2912154848 sameAs 2912154848 @default.
• W2912154848 citedByCount "0" @default.
• W2912154848 crossrefType "journal-article" @default.
• W2912154848 hasAuthorship W2912154848A5002578778 @default.
• W2912154848 hasAuthorship W2912154848A5005122036 @default.
• W2912154848 hasAuthorship W2912154848A5021660874 @default.
• W2912154848 hasAuthorship W2912154848A5028030321 @default.
• W2912154848 hasAuthorship W2912154848A5062140174 @default.
• W2912154848 hasAuthorship W2912154848A5068478538 @default.
• W2912154848 hasAuthorship W2912154848A5074684369 @default.
• W2912154848 hasAuthorship W2912154848A5075899439 @default.
• W2912154848 hasAuthorship W2912154848A5082158998 @default.
• W2912154848 hasAuthorship W2912154848A5089395073 @default.
• W2912154848 hasBestOaLocation W29121548481 @default.
• W2912154848 hasConcept C126322002 @default.
• W2912154848 hasConcept C167135981 @default.
• W2912154848 hasConcept C177713679 @default.
• W2912154848 hasConcept C194828623 @default.
• W2912154848 hasConcept C2776376669 @default.
• W2912154848 hasConcept C2777120189 @default.
• W2912154848 hasConcept C2777408962 @default.
• W2912154848 hasConcept C2777628635 @default.
• W2912154848 hasConcept C2778384902 @default.
• W2912154848 hasConcept C2911091166 @default.
• W2912154848 hasConcept C38180746 @default.
• W2912154848 hasConcept C71924100 @default.
• W2912154848 hasConcept C72563966 @default.
• W2912154848 hasConceptScore W2912154848C126322002 @default.
• W2912154848 hasConceptScore W2912154848C167135981 @default.
• W2912154848 hasConceptScore W2912154848C177713679 @default.
• W2912154848 hasConceptScore W2912154848C194828623 @default.
• W2912154848 hasConceptScore W2912154848C2776376669 @default.
• W2912154848 hasConceptScore W2912154848C2777120189 @default.
• W2912154848 hasConceptScore W2912154848C2777408962 @default.
• W2912154848 hasConceptScore W2912154848C2777628635 @default.
• W2912154848 hasConceptScore W2912154848C2778384902 @default.
• W2912154848 hasConceptScore W2912154848C2911091166 @default.
• W2912154848 hasConceptScore W2912154848C38180746 @default.
• W2912154848 hasConceptScore W2912154848C71924100 @default.
• W2912154848 hasConceptScore W2912154848C72563966 @default.
• W2912154848 hasIssue "Supplement 1" @default.
• W2912154848 hasLocation W29121548481 @default.
• W2912154848 hasOpenAccess W2912154848 @default.
• W2912154848 hasPrimaryLocation W29121548481 @default.
• W2912154848 hasRelatedWork W1984304831 @default.
• W2912154848 hasRelatedWork W2006959798 @default.
• W2912154848 hasRelatedWork W2072467223 @default.
• W2912154848 hasRelatedWork W2406430194 @default.
• W2912154848 hasRelatedWork W2443282966 @default.
• W2912154848 hasRelatedWork W2920939747 @default.
• W2912154848 hasRelatedWork W2964769311 @default.
• W2912154848 hasRelatedWork W3025110062 @default.
• W2912154848 hasRelatedWork W3033331552 @default.
• W2912154848 hasRelatedWork W4292539933 @default.
• W2912154848 hasVolume "132" @default.
• W2912154848 isParatext "false" @default.
• W2912154848 isRetracted "false" @default.
• W2912154848 magId "2912154848" @default.
• W2912154848 workType "article" @default.